Valuation : Viatris Inc.

Market Cap 18.96B 16.34B 15.47B 14.02B 26.31B 1,812B 26.44B 184B 70.66B 922B 71.22B 69.66B 2,912B P/E 2026 *
53.2x
P/E 2027 * 32.2x
Enterprise Value 31.03B 26.73B 25.31B 22.94B 43.04B 2,964B 43.26B 301B 116B 1,508B 117B 114B 4,765B EV / Sales 2026 *
2.1x
EV / Sales 2027 * 1.99x
Free-Float
91.44%
Yield 2026 *
3.08%
Yield 2027 * 3.16%
1 day-0.04%
1 week-1.97%
Current month+1.47%
1 month+1.29%
3 months+2.72%
6 months+16.58%
Current year+34.25%
1 week 13.81
Extreme 13.812
14.27
1 month 13.81
Extreme 13.812
14.64
Current year 10.52
Extreme 10.52
15.73
1 year 8.09
Extreme 8.092
15.73
3 years 6.45
Extreme 6.452
15.73
5 years 6.45
Extreme 6.452
15.73
10 years 6.45
Extreme 6.452
15.73
Manager TitleAgeSince
Chief Executive Officer 63 31/03/2023
Director of Finance/CFO 59 07/05/2026
Chief Tech/Sci/R&D Officer - 14/12/2023
Director TitleAgeSince
Director/Board Member 78 15/11/2020
Director/Board Member 78 15/11/2020
Director/Board Member 62 15/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-1.97% - - 18.96B
-0.65%-2.93%+47.52%+87.34% 994B
-0.29%-3.51%+48.78%+63.27% 640B
+0.83%+0.26%+16.76%+72.52% 454B
-0.38%-3.59%+28.24%+35.57% 337B
-0.09%-13.54%+10.08%+26.87% 261B
-0.43%-2.48%-2.07%+11.48% 246B
-1.34%-13.70%+33.47%+44.18% 204B
-3.44%-7.51%-20.08%-59.58% 190B
-0.75%-4.82%+21.94%+86.55% 178B
Average -0.66%-5.76%+20.52%+40.91% 389.42B
Weighted average by Cap. -0.51%-4.42%+29.87%+55.71%

Financials

2026 *2027 *
Net sales 14.79B 12.74B 12.06B 10.93B 20.51B 1,413B 20.62B 143B 55.09B 719B 55.53B 54.31B 2,271B 15.06B 12.97B 12.29B 11.14B 20.89B 1,439B 21B 146B 56.11B 732B 56.56B 55.31B 2,313B
Net income 221M 190M 180M 163M 306M 21.09B 308M 2.14B 823M 10.73B 829M 811M 33.91B 407M 350M 332M 301M 564M 38.86B 567M 3.94B 1.52B 19.77B 1.53B 1.49B 62.47B
Net Debt 12.07B 10.4B 9.84B 8.92B 16.74B 1,153B 16.82B 117B 44.95B 586B 45.31B 44.32B 1,853B 11.08B 9.55B 9.04B 8.19B 15.37B 1,058B 15.45B 107B 41.28B 538B 41.61B 40.69B 1,702B
Logo Viatris Inc.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
30,000
Date Price Change Volume
11/09/26 €14.15 +1.56% 0
10/09/26 €13.94 -2.30% 0
09/09/26 €14.26 -0.04% 0
08/09/26 €14.27 +3.32% 0
07/09/26 €13.81 -5.07% 0
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
16.51USD
Average target price
18.67USD
Spread / Average Target
+13.06%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!